Advances in the treatment of BC have been attributed largely to early detection and identification of specific therapeutic targets, such as estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and progesterone receptor (PR). This evidence concerns the gene ERBB2 and breast cancer.